Breast Cancer

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

China’s NMPA approved bireociclib for 2 indications in adult patients with HR+/HER2– breast cancer.

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Alexis LeVee, MD, discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC.

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Challenges may arise as there could be unintended consequences on oncologic drug development, access, and innovation.

Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Arielle Heeke, MD, highlights the role of adjuvant abemaciclib and ribociclib in patients with HR-positive, HER2-negative, early breast cancer.

No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.